Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a Buy rating for SAB Biotherapeutics (NASDAQ:SABS) and maintained a price target of $25.
September 09, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital's analyst Keay Nakae has reiterated a Buy rating for SAB Biotherapeutics, maintaining a $25 price target. This suggests confidence in the company's future performance.
The reaffirmation of a Buy rating and a $25 price target by Chardan Capital indicates a positive outlook on SAB Biotherapeutics' stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100